The Cooper Companies, Inc. $COO Shares Sold by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. reduced its stake in The Cooper Companies by 21% in the first quarter, selling 5,273 shares, while its remaining holdings valued at $1.67 million.
• Several institutional investors, including Mirae Asset Global Investments Co. Ltd. and DAVENPORT & Co LLC, increased their positions in Cooper Companies during the same period, reflecting a level of confidence in the stock.
• The company's stock price has been affected by analysts' ratings, with Wells Fargo & Company and Robert W. Baird both cutting their price targets significantly, while others have maintained or raised their ratings, leading to a consensus rating of "Moderate Buy."

Banco Bilbao Vizcaya Argentaria S.A. decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 21.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,823 shares of the medical device company's stock after selling 5,273 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Cooper Companies were worth $1,666,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Cooper Companies by 15.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,189 shares of the medical device company's stock valued at $2,194,000 after acquiring an additional 3,440 shares during the period. DAVENPORT & Co LLC increased its position in shares of Cooper Companies by 13.4% in the first quarter. DAVENPORT & Co LLC now owns 4,335 shares of the medical device company's stock valued at $366,000 after buying an additional 513 shares in the last quarter. Cerity Partners LLC increased its position in shares of Cooper Companies by 6.6% in the first quarter. Cerity Partners LLC now owns 17,113 shares of the medical device company's stock valued at $1,443,000 after buying an additional 1,054 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Cooper Companies by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 23,390 shares of the medical device company's stock valued at $1,972,000 after buying an additional 680 shares in the last quarter. Finally, Cetera Investment Advisers increased its position in shares of Cooper Companies by 1.3% in the fourth quarter. Cetera Investment Advisers now owns 24,049 shares of the medical device company's stock valued at $2,211,000 after buying an additional 312 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on COO shares. Wells Fargo & Company cut their price objective on Cooper Companies from $118.00 to $93.00 and set an "overweight" rating for the company in a research report on Friday, May 30th. Robert W. Baird dropped their price target on Cooper Companies from $107.00 to $97.00 and set an "outperform" rating for the company in a research report on Friday, May 30th. Mizuho dropped their price target on Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a research report on Wednesday, July 16th. UBS Group raised Cooper Companies to a "buy" rating in a research note on Tuesday, June 17th. Finally, Needham & Company LLC raised Cooper Companies from a "hold" rating to a "buy" rating and set a $94.00 price objective on the stock in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $96.73.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $75.22 on Friday. The Cooper Companies, Inc. has a 52 week low of $65.00 and a 52 week high of $112.38. The business's fifty day simple moving average is $72.18 and its 200-day simple moving average is $78.32. The firm has a market cap of $15.04 billion, a PE ratio of 36.51, a price-to-earnings-growth ratio of 1.78 and a beta of 1.00. The company has a quick ratio of 1.23, a current ratio of 2.10 and a debt-to-equity ratio of 0.30.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings results on Thursday, May 29th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.93 by $0.03. Cooper Companies had a return on equity of 9.60% and a net margin of 10.39%.The business had revenue of $1 billion for the quarter, compared to analyst estimates of $995.12 million. During the same quarter in the prior year, the company posted $0.85 EPS. The company's quarterly revenue was up 6.3% on a year-over-year basis. Cooper Companies has set its FY 2025 guidance at 4.050-4.110 EPS. Equities analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.